OncoMatch

OncoMatch/Clinical Trials/NCT06093438

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Is NCT06093438 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Toripalimab for cervical cancer.

Phase 1/2RecruitingTianjin Medical University Cancer Institute and HospitalNCT06093438Data as of Jun 2026Location: China

Treatment: ToripalimabTo explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Toripalimab

Cancer type

Cervical Cancer

Disease stage

Required: Stage IIIB, IIIC, IVA

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75
Female only

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: any prior treatment

Patients received any form of treatment before enrollment

Lab requirements

Blood counts

Hemoglobin ≥ 9.0 g/dl; Neutrophils ≥ 2000 cells/μl; Leukocytes ≥ 4 × 10^9/L; Platelets ≤ 100 × 10^9/L

Kidney function

Serum urea nitrogen (BUN) ≤ 1.5 × upper normal limit (UNL); Serum creatinine (Cr) ≤ 1.5 × upper normal limit (UNL)

Liver function

Serum ALT/AST ≤ 2.5×UNL; Serum Total bilirubin ≤ 1.5× UNL

Cardiac function

No obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease

Adequate hematological, renal and hepatic functions: ... Impaired hematological, renal or hepatic functions: Hemoglobin < 9.0 g/dl, Neutrophils < 2000 cells/μl; Leukocytes < 4 × 10^9/L; Platelets > 100 × 10^9/L; Serum ALT/AST > 2.5×UNL; Serum Total bilirubin > 1.5× UNL; Serum urea nitrogen (BUN) > 1.5 × upper normal limit (UNL); Serum creatinine (Cr) > 1.5 × upper normal limit (UNL)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06093438 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage IIIB or IIIC or IVA is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify